Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The stock price of Novavax, Inc. (NASDAQ: NVAX) fell by over 15% during intraday trading today. This is why it happened.

Novavax (NVAX) Stock: Why The Price Fell Today

Los Angeles, California--(Newsfile Corp. - December 2, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 2, 2021 and October 19, 2021, inclusive (the...

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Investors aren't convinced that Novavax's current coronavirus vaccine can handle the omicron variant.

Why Novavax Stock Is in Retreat Mode Today

Novavax, Inc. (NVAX) Presents at Evercore ISI's 4th Annual HealthCONx Virtual Conference (Transcript)

Covid-19 vaccine developer Novavax's stock rallied by about 4% over the last three trading days, while rising by almost 8% in Tuesday's trading, following the discovery of a highly mutated new strain of the novel coronavirus that has been designated as a variant of concern by the World Health.

With A Delayed Vaccine And New Virus Variants Emerging, Where Does Novavax Stock Stand?

Is Novavax's COVID Vaccine Authorization in the Philippines a Game-Changer?

Pinterest

Block

Patience will pay off handsomely if investors buy into this innovative trio.

3 Surefire Growth Stocks to Buy in December

NEW YORK, Dec. 1, 2021 /PRNewswire/ -- WHY:  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NVAX LOSS ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Novavax, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NVAX

NEW ORLEANS, Dec. 1, 2021 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors with losses in excess of $100,000 that they have until January 11, 2022 to file lead plaintiff applications in a securities class action lawsuit against Novavax, Inc. (NasdaqGS: NVAX), if they purchased the Company's securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period"). This action is pending in the United States District Court for the District of Maryland.

CLAIMSFILER ALERTS NOVAVAX Investors to Lead Plaintiff Deadline in Class Action Lawsuit Against Novavax, Inc. - NVAX

New York, New York--(Newsfile Corp. - December 1, 2021) -  The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Novavax, Inc. (NASDAQ: NVAX).Shareholders who purchased shares of NVAX during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/novavax-inc-loss-submission-form-2/?id=21834&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Novavax, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 11, 2022 - (NVAX)

San Francisco, California--(Newsfile Corp. - December 1, 2021) - Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now.Class Period: Mar. 2, 2021 - Oct. 19, 2021Lead Plaintiff Deadline: Jan. 11, 2022Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: NVAX@hbsslaw.com 844-916-0895Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax's progress toward successfully developing its COVID-19 vaccin

NVAX LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Novavax (NVAX) Investors with Losses to Contact Firm's Attorneys, Securities Fraud Class Action Pending

Los Angeles, California--(Newsfile Corp. - December 1, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Novavax, Inc. ("Novavax" or "the Company") (NASDAQ: NVAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 2, 2021 and October 19, 2021, inclusive (the...

SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Novavax, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Johnson & Johnson

Merck

Pfizer

Vir Biotechnology

Could biotech stocks be top buys as the world battles a new Covid-19 variant?

5 Biotech Stocks For Your December 2021 Watchlist

SAN DIEGO--(BUSINESS WIRE)---- $NVAX #COVID19--Novavax, Inc. (NVAX) Misled Shareholders Regarding Approval of its COVID Vaccine

Novavax, Inc. Shareholder Alert: Robbins LLP Informs Reminds of Class Action Against Novavax, Inc. (NVAX)

New York, New York--(Newsfile Corp. - November 30, 2021) -  Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Novavax, Inc. (NASDAQ: NVAX).CLICK HERE FOR MORE DETAILS:https://claimyourloss.com/securities/novavax-inc-loss-submission-form-2/?id=21769&from=5

NVAX Lawsuit Filed: Jakubowitz Law Pursues Claims on Behalf of Novavax, Inc. Shareholders

NVAX stock has been listless in 2021, which is frustrating investors. Yet, Novavax is making headway on the international regulatory front.

Novavax Can Still Find Growth Opportunities Abroad

But not all coronavirus stocks were on the rise.

Why Novavax and Pfizer Are Trouncing the Market Today

Pfizer expects Comirnaty to account for $36B in revenue in FY21 and $29B in sales in FY22. Pfizer recently filed for the Emergency Use Authorization for its COVID-19 antiviral candidate, PAXLOVID, which is expected to bring in $24B in sales in FY22.

Novavax Vs. Pfizer Stock: Which Is The Better Buy?

Things appear to be aligning for a great month for this vaccine stock.

Why Novavax Stock Could Skyrocket in December

Boston, Massachusetts--(Newsfile Corp. - November 29, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or...

NVAX Investor Alert: Class Action Lawsuit Filed

BioNTech SE

Moderna

Another variant of the coronavirus, Omicron, is up on the WHO-identified list. Several mutations of this variant spark fears of high resistance to the COVID-19 vaccines.

Omicron Fears Fuel Rally in Vaccine Stocks: Will It Continue?

As the Novavax vaccine becomes approved by more and more countries, NVAX stock will likely climb in the near-to-medium term. The post Novavax Is a Buy Based on Its Outlook, But Not for the Long Haul appeared first on InvestorPlace.

Novavax Is a Buy Based on Its Outlook, But Not for the Long Haul

The omicron variant dealt the stock market a blow, but these vaccine stocks promise investors a way to cash in while combatting Covid-19. The post 5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market appeared first on InvestorPlace.

5 Vaccine Stocks to Watch as New Covid-19 Variant Strikes the Market

CVS Health

Check out these health care stocks that are heating up in the stock market right now.

4 Top Health Care Stocks To Watch In The Stock Market Today

Novavax (NVAX) is likely to generate huge revenues as the company has started filing approvals for emergency use of its COVID-19 vaccine in multiple nations.

News for Novavax Stock (NVAX)